CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 24, 2009--
Alkermes, Inc. (NASDAQ: ALKS) today announced that it will webcast its
Research and Development (R&D) Day meeting being held on Tuesday, April
7, 2009 at Alkermes’ headquarters in Cambridge, Massachusetts. The
webcast will begin at 8:30 a.m. EDT and will run until approximately
10:30 a.m. EDT. At the meeting, members of the Alkermes team and guest
speakers will provide an update on the company's proprietary pipeline
and overview the scientific rationale underlying its R&D strategy.
A live webcast of the event will be available on the investor relations
section of the company's website at www.alkermes.com.
To ensure a timely connection to the webcast, it is recommended that
users register at least 15 minutes prior to the scheduled webcast. This
webcast will be archived for 14 days.
Alkermes, Inc. is a fully integrated biotechnology company committed to
developing innovative medicines to improve patients' lives. Alkermes
developed, manufactures and commercializes VIVITROL® for
alcohol dependence and manufactures RISPERDAL® CONSTA®
for schizophrenia. Alkermes' robust pipeline includes extended-release
injectable, pulmonary and oral products for the treatment of prevalent,
chronic diseases, such as central nervous system disorders, addiction
and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has
research facilities in Massachusetts and a commercial manufacturing
facility in Ohio.